DELRAY BEACH, Fla., June 17, 2005 (PRIMEZONE) -- Hard To Treat Diseases, Incorporated (HTTD) (Pink Sheets:HTDS) announces today that the Court's decision on the trial of the Company's claims is pending.
The presentation of evidence and legal arguments concluded on June 15th and as indicated on the Court's website:
"DECISION PENDING: Hard to Treat Diseases, Inc. v. Shinn et al., 04-800010. The trial has concluded and the court has granted the parties an additional ten days to submit proposed findings of fact and conclusions of law. The court's decision will be filed with the clerk of court shortly thereafter and a precis of the decision will be published on this website. Persons desiring a copy of the decision should make appropriate arrangements with the clerk of court."
The Court's decision will be available on their website: http://us.geocities.com/uscts
Upon publication, a complete copy of the Court's decision can be viewed on the Company's website at: www.htdsotc.com
The Company recognizes that the courts are open to the public and does not in any way intend to suggest otherwise, but the Company does request that interested persons be respectful of the Court's time and direct questions to the Clerk of the Courts, as identified in the Court's announcement.
HTTD's shareholders and investors will be kept informed of all public developments as they occur regarding the Company's matters. In order to ensure the confidentiality of the Company's business and legal strategies and not to undermine the authority of the Court, certain specific information may not be immediately available. Once such information can be revealed, it will be publicly disclosed to all shareholders.
HTTD is currently involved in litigation regarding the rights to Tubercin(r). Additional information and details regarding the litigation can be viewed at our website at: www.htdsotc.com
Cautionary Note Regarding Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard to Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.